Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 4Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Rheumatoid Arthritis, Systemic Juvenile 1Rectal Neoplasms 1Primary Myelofibrosis 1Periodic Fevers Syndrome 1Pancreatic Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Mevalonate Kinase Deficiency 1Metastatic Pancreatic Ductal Adenocarcinoma 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Intestinal Neoplasms 1Gastrointestinal Neoplasms 1Cryopyrin-Associated Periodic Syndromes 1Colorectal Neoplasms 1Colonic Neoplasms 1Clonal Cytopenia of Undetermined Significance 1Carcinoma, Renal Cell 1Carcinoma, Ductal 1Carcinoma 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1Arthritis, Juvenile 1Arthralgia 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Oxaliplatin 29Fluorouracil 25Leucovorin 20Capecitabine 18Irinotecan 17Bevacizumab 14Cisplatin 12Surveys and Questionnaires 11Gemcitabine 9Drug Therapy 9Standard of Care 8Nivolumab 7Cetuximab 7pembrolizumab 6S 1 (combination) 6Cyclophosphamide 6atezolizumab 5Specimen Handling 5Endoscopic Mucosal Resection 5Educational Status 5Docetaxel 5Blood Specimen Collection 5fludarabine 4aldesleukin 4Radiotherapy 4Radiosurgery 4Pemetrexed 4IFL protocol 4Folfox protocol 4Everolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gastrointestinal Neoplasms × canakinumab × Clear all
NCT05984602 2026-03-30

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

NYU Langone Health

Phase 1 Active not recruiting
9 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡